
	Where results make sense

Topic: Tetrabenazine

Related Topics

Orphan drug

Antipsychotic

In the News (Mon 28 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Blogger: Email Post to a Friend
		Prestwick Pharmaceuticals' tetrabenazine may be a safe and viable treatment option for patients with hyperkinetic movement disorders who have a prior history of depression, according to research presented recently.
		During tetrabenazine treatment, 50 patients (18.4%) had an exacerbation of their depression or required a change in antidepressant (15.4%) and 28 patients (11.4%) experienced depression for the first time.
		Tetrabenazine is available in some European markets and Australia as Xenazine and in Canada as Nitoman for the treatment of hyperkinetic movement disorders.
	www.blogger.com /email-post.g?blogID=9493808&postID=111067681768798237 (397 words)

	Orphan Australia - Consumer Medicine Information - Tetrabenazine
		Tetrabenazine is used for the treatment of diseases, which cause jerky, irregular, uncontrollable movements such as Huntington's chorea, senile chorea and hemiballismus.
		Tetrabenazine Tablets should only be used by the person for whom it was prescribed.
		Tetrabenazine Tablets are available in plastic bottles containing 112 tablets.
	www.orphan.com.au /tetrabenazine_CMI.htm (983 words)

	Business Wire: Tetrabenazine Receives ``Fast Track'' Designation From the FDA for Chorea Associated with ... (Site not responding. Last check: 2007-10-21)
		Tetrabenazine Receives ``Fast Track'' Designation From the FDA for Chorea Associated with Huntington's Disease.
		Tetrabenazine is being evaluated for the treatment of chorea associated with Huntington's disease.
		Currently in pivotal clinical testing in the United States, tetrabenazine is a novel dopamine depletor that works by selectively blocking the VMAT2 transporter in the CNS.
	www.highbeam.com /library/doc0.asp?DOCID=1G1:122089447&refid=ip_encyclopedia_hf (178 words)

	WE MOVE - Treatment of Pediatric Movement Disorders - Medication: Tetrabenazine and Reserpine
		Tetrabenazine (Nitoman®, not available in the US) and reserpine act by depleting the supply of dopamine, norepinephrine, and serotonin in nerve terminals, thereby decreasing the amount available for release.
		Tetrabenazine has also been reported to be useful in chorea and tic disorders.
		Both tetrabenazine and reserpine may cause parkinsonism; signs of parkinsonism must be carefully watched for, since mild parkinsonian bradykinesia may be difficult to detect in a child with generalized dystonia.
	www.wemove.org /pediatric_treatment/medication_tetrabenazine.html (174 words)

	Antipsychotic - Wikipedia, the free encyclopedia
		Tetrabenazine (NitomanÂ® in Canada and XenazineÂ® in New Zealand and some parts of Europe) is similar in function to antipsychotic drugs, though isn't generally considered an antipsychotic itself.
		Also, rather than having the to potential to cause tardive dyskinesia that most antipsychotics have, tetrabenazine can actually be an effective treatment for the condition.
		The typical antipsychotic drugs are now out of patent meaning any pharmaceutical company is legally allowed to produce cheap generic versions of these medications.
	en.wikipedia.org /wiki/Neuroleptic (1439 words)

	Tetrabenazine
		Tetrabenazine is currently in stock and is therefore available for immediate despatch to you.
		Tetrabenazine is used for the treatment of diseases, which cause jerky, irregular, uncontrollable movements such as Huntington's chorea, senile chorea, tardive dyskinesia and hemiballismus.
		Tetrabenazine should only be used in tardive dyskinesia when other treatment options have failed.
	www.hdlighthouse.org /see/drugs/tbz.htm (1364 words)

	Cambridge Laboratories \| Therapeutic Areas \| Gelclair (Site not responding. Last check: 2007-10-21)
		Tetrabenazine has two modes of action; it depletes pre-synaptic stores of monoamines and has a postsynaptic receptor blocking action.
		Tetrabenazine is mainly used to control movement disorders associated with diseases of the brain and nervous system, such as Huntington's Disease.
		Tetrabenazine can also be used if it is not possible to stop or change the antipsychotic.
	www.camb-labs.com /xenazine.html (286 words)

	pp10_07_articles_Magnets_used_to_treat_depression_2-25-05
		NEW ORLEANS--(BUSINESS WIRE)--March 8, 2005--New data show the investigational therapy tetrabenazine may be a safe and viable treatment option for patients with hyperkinetic movement disorders who have a prior history of depression, according to research presented this week at the 9th International Congress of Parkinson's Disease and Movement Disorders in New Orleans.
		Previous studies have demonstrated that tetrabenazine, a dopamine depleter that works by selectively blocking vesicular monoamine transporter 2 (VMAT2), improves the symptoms associated with a number of hyperkinetic movement disorders.
		Prestwick was granted both fast track and orphan designation by the FDA for tetrabenazine as a therapy for chorea associated with Huntington's Disease.
	vnsdepression.com /pp10-063_articles_3-8-05-TetrabenazineinPatients.htm (782 words)

	MDS: Tetrabenazine Shows Benefits in Treatment of Tourette Syndrome
		MIAMI, FL -- November 15, 2002 -- Tetrabenazine shows a "distinct advantage" over traditional dopamine receptor blocking drugs used to treat Tourette syndrome and is not associated with tardive dyskinesia, researchers report.
		Previous research indicates that tetrabenazine shows efficacy for the treatment of hyperkinetic movement disorders such as Huntington's disease and tardive dyskinesia, with a marked reduction in the associated hyperkinesia.
		During the specified study period, 354 subjects were treated at Baylor with tetrabenazine, and 78 received a diagnosis of TS, with a mean of 22.8 months of follow-up.
	www.docguide.com /dg.nsf/PrintPrint/A36846CB5870B6A085256C72005792E0 (509 words)

	Neuroendocrine evidence that tetrabenazine is a dopamine antagonist -- Login et al. 172 (2): 225 -- Experimental ...
		Neuroendocrine evidence that tetrabenazine is a dopamine antagonist -- Login et al.
		Neuroendocrine evidence that tetrabenazine is a dopamine antagonist
		In vivo and in vitro, tetrabenazine induces biological responses
	www.ebmonline.org /cgi/content/abstract/172/2/225 (248 words)

	Prestwick submits application for Huntingtons disease drug - Pharmaceutical Business Review
		Tetrabenazine is a highly selective and reversible dopamine depletor that works by inhibiting vesicular monoamine transporter 2 (VMAT2).
		Tetrabenazine is approved for marketing outside the US in eight countries and is under regulatory review for approval in several additional countries.
		Prestwick's application is supported by phase III clinical data that suggests tetrabenazine is significantly more effective than placebo in treating patients' chorea associated with Huntington's disease, with many patients demonstrating marked to good improvement.
	www.pharmaceutical-business-review.com /article_news.asp?guid=502B5B46-5BB7-4A6F-B49C-98F6843A969B (278 words)

	NetDoctor.co.uk - Information about drugs for Patients
		Tetrabenazine is mainly used to control movement disorders associated with diseases of the brain and nervous system, such as Huntington's chorea, but can also be used to control movement disorders caused by antipsychotic medicines.
		Tetrabenazine should not be taken at the same time as, or for 14 days following a course of monoamine oxidase inhibitor (MAOI) antidepressants, as this can cause restlessness, disorientation and confusion.
		Tetrabenazine should not be taken with alcohol as this may increase the drowsiness experienced.
	www.netdoctor.co.uk /medicines/showpreparation.asp?id=2566 (683 words)

	ANA: Tetrabenazine Appears to Significantly Improve Debilitating Movement Disorder Associated with Huntington's Disease
		After 12 weeks, the adjusted mean tetrabenazine chorea score declined by 5.0 points, while scores for the placebo group declined by 1.5 points (p(less than)0.0001).
		Tetrabenazine was superior to placebo as assessed by the CGI scale (p=0.007).
		This study of tetrabenazine, called "TETRA-HD," was organized and conducted by the Huntington Study Group (HSG), a non-profit, cooperative group of Huntington's Disease experts from medical centers in North America, Europe and Australia who are dedicated to improving treatment for persons affected by Huntington's Disease.
	www.docguide.com /dg.nsf/PrintPrint/F017A9F99B95DDD185256F23004FBE33 (709 words)

	Patent 5278308: Iodine derivatives of tetrabenazine
		This invention relates to a series of iodine derivatives of tetrabenazine (3-(2-methylpropyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-benzo[a]quin olizin-2-one, TBZ,1), a monoamine storage-site selective inhibitor, which iodine derivatives are useful as imaging agents for evaluation of the central nervous system (CNS) neuronal system.
		Tetrabenazine, 3-(2-methylpropyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H -benzo[a]quinolizin-2-one (TBZ), ##STR4## is an analog of reserpine which displays a similar biological profile.
		Tetrabenazine produces a similar effect; however, the drug effects of TBZ are of a shorter duration and do not cause irreversible damage to neurons (Cooper J. R., Bloom F. E., Ruth R. H., In Biochemical Basis of Neurochemistry, 5th ed., Oxford University Press, New York, 1986, p.
	www.freepatentsonline.com /5278308.html (4040 words)

	New Drug Is Effective in Treating HD Chorea
		A phase 3 clinical trial of tetrabenazine showed the drug to be effective in the treatment of chorea associated with Huntington's disease (HD).
		After 12 weeks, the chorea score for the tetrabenazine group had decreased by 5 points, whereas the scores for the placebo group had decreased by only 1.5 points.
		Tetrabenazine also was proven to be superior to placebo on the Clinical Global Impression Scale, which assesses severity of illness and change in clinical condition.
	www.pharmacytimes.com /article.cfm?ID=1777 (233 words)

	Canadian Pharmacy, Canada Drugs, Online Pharmacy Prescriptions (Site not responding. Last check: 2007-10-21)
		Nitoman (Tetrabenazine) is used in the treatment of hyperkinetic movement disorders such as Huntington's chorea, Hemiballismus, Senile Chorea, Tic and Gille's de la Tourette Syndrome and Tardive Dyskinesia.
		Nitoman (Tetrabenazine) is not indicated for the treatment of levodopa-induced dyskinetic/choreiform movements (see Warnings).
		Nitoman (Tetrabenazine) is contraindicated in patients with a current episode or a history of clinical depression.
	www.abconlinepharmacy.com /test1/ns1/customer/product3469-c-p1 (416 words)

	AAN - [AAN newsletter] - February 1999 (Site not responding. Last check: 2007-10-21)
		Tetrabenazine has been included within their portfolio of orphan products following recent transitions from Roche and Virgo Healthcare.
		As a result, the supply of Tetrabenazine can now be expected to be more consistent, and will be supported by our dedicated team.
		The PBS listing of Tetrabenzazine was altered from a general listing to "Authority Required" on May 1st, with repeats increasing from 2 to 5.
	www.aan.org.au /newsletter/nlju99_7.htm (175 words)

	Tetrabenazine (Site not responding. Last check: 2007-10-21)
		You can also try tetrabenazine (related to reserpine), but may only be available at certain centers or from Europe -- it's made by Roche and is only available by compassionate plea.
		Tetrabenazine is also available in the UK; according to the British National Formulary it is "mainly used to control movement disorders in Huntington's chorea and related disorders.
		I understand that tetrabenazine acts as a dopamine depleter similar to reserpine and that depression is a common side effect.
	www.dr-bob.org /tips/split/Tetrabenazine.html (361 words)

	Canadian Corporate News: Prestwick Pharmaceuticals Acquires Rights to Commercialize Nitoman -Tetrabenazine- in Canada.@ ... (Site not responding. Last check: 2007-10-21)
		Prestwick Pharmaceuticals, Inc., a CNS specialty pharmaceutical company, announced today the acquisition of rights to commercialize tetrabenazine in Canada under the brand name Nitoman(TM) from Cambridge Laboratories, a pharmaceutical company based in the United Kingdom (UK).
		Tetrabenazine is a dopamine depletor approved in Canada for the treatment of a series of hyperkinetic movement disorders.
		Approximately 50,000 Canadians suffer from these disorders, which are characterized by excessive, involuntary purposeless and...
	www.highbeam.com /library/doc0.asp?DOCID=1G1:122249784&refid=ip_encyclopedia_hf&COOKIE=NO&token=278A3B0DD1CB48B29FDAEC4E3E04F1A8 (181 words)

	HD Blog: Tetrabenazine Data To Be Presented
		Tetrabenazine is a first-of-its-kind, dopamine depletor currently available in some European markets and Australia as XENAZINE(TM), and in Canada as NITOMAN(R) for the treatment of hyperkinetic movement disorders.
		Tetrabenazine study results to be presented at the 18th Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders at the ANA meeting include:
		The study "A Randomized, Double-blind, Placebo-controlled Study of Tetrabenazine in Patients with Huntington's Disease", called "TETRA-HD", was organized and conducted by the Huntington Study Group (HSG), a non-profit, cooperative group of Huntington's disease experts from medical centers in North America, Europe and Australia who are dedicated to improving treatment for persons affected by Huntington's disease.
	www.huntingtons.info /MT/archives/2004/09/tetrabenazine_d.html (616 words)

	Epilepsy News : Epilepsy.com/Professionals
		New data reported on tetrabenazine in patients with movement disorders and a history of depression; findings presented at 9th International Congress of Parkinson's Disease and Movement Disorders.
		New data show the investigational therapy tetrabenazine may be a safe and viable treatment option for patients with hyperkinetic movement disorders who have a prior history of depression, according to research presented at the 9th International Congress of Parkinson's Disease and Movement Disorders in New Orleans.
		During tetrabenazine treatment, 50 patients had an exacerbation of their depression or required a change in antidepressant and 28 patients experienced depression for the first time.
	professionals.epilepsy.com /newsfeed/pr_1110983406.html (304 words)

	BCM-Neurology-Parkinson's Disease Center and Movement Disorders-Tetrabenazine
		In contrast, tetrabenazine produces a reversible depletion of storage granules with full recovery within 12 to 24 hours after the drug is stopped.
		Alpha-methylparatyrosine, a competitive inhibitor of the rate-limiting enzyme tyrosine hydroxylase which catalyzes the conversion of L?tyrosine to L-dopa, may potentiate the effects of reserpine and tetrabenazine.
		Tetrabenazine (TBZ), a benzoquinolizine compound that depletes cerebral monoamines and blocks dopamine receptors in rat brain, was first introduced in 1960 as an antipsychotic drug.
	www.bcm.edu /neurology/struct/parkinson/tetrabenazine.html (1151 words)

	Globeinvestor.com: New Data Reported on Tetrabenazine for the Treatment of Pediatric Hyperkinetic Movement Disorders
		Clinical study investigators concluded that tetrabenazine was an effective and well-tolerated treatment for severe hyperkinetic movement disorders among children who are resistant to other medications, according to new data presented today at the 57th Annual Meeting of the American Academy of Neurology in Miami Beach.
		Sixteen patients continued tetrabenazine along with at least one other medication to control movements, while movements were sufficiently controlled with tetrabenazine alone in six patients.
		Nine patients (30%) discontinued tetrabenazine due to behavior changes (3), sedation (3), worsening or lack of improvement in movements (2) and major depression (1).
	www.globeinvestor.com /servlet/ArticleNews/print/CCNM/20050415/0415007n (591 words)

	HD Blog: Tetrabenazine Gets 'Fast Track'
		The Fast Track Program is designed to expedite the review of drug compounds for the treatment of patients with serious or life-threatening diseases where there is an unmet medical need for new therapeutic approaches.
		Tetrabenazine is approved for use in several European countries and Australia as Xenazine(TM), and in Canada as Nitoman(TM).
		Prestwick is currently conducting pivotal trials in the U.S. with its lead compound, tetrabenazine, and plans to file an NDA in the very near future.
	www.huntingtons.info /MT/archives/2004/09/tetrabenazine_g.html (361 words)

	BioSpace News for (Site not responding. Last check: 2007-10-21)
		Phase III clinical data presented yesterday during the satellite symposia held in conjunction with the American Neurological Association 129th annual meeting in Toronto, Ontario, demonstrated that the investigational therapy tetrabenazine is an effective treatment for chorea associated with Huntington's Disease (HD).
		HD is a debilitating CNS disorder marked by incessant involuntary movements for which there is no approved therapy in the United States.
		Tetrabenazine is a novel dopamine depletor currently on the market in parts of Europe, Australia and Canada for a variety of hyperkinetic movement disorders.
	www.biospace.com /news_company.cfm?CompanyID=672420 (965 words)

	news283
		annual meeting of the American Academy of Neurology, reports that tetrabenazine is an effective and well-tolerated treatment for severe hyperkinetic movement disorders among children who are resistant to other medication.
		The study involved the treatment of 30 children aged 18 years and younger with tetrabenazine.
		A retrospective chart review was conducted over the course of 18 years to assess the efficacy and tolerability of tetrabenazine among these patients.
	www.dial.org.uk /news/news283/news283.html (140 words)

	Tetrabenazine may be suitable for patients with history of depression - Pharmaceutical Business Review
		Tetrabenazine may be suitable for patients with history of depression - Pharmaceutical Business Review
		Tetrabenazine may be suitable for patients with history of depression
		9 Mar 2005, 17:53 GMT - Previous studies have demonstrated that tetrabenazine improves the symptoms associated with a number of hyperkinetic movement disorders, which include Huntington's disease, other choreas and tardive dyskinesia.
	www.pharmaceutical-business-review.com /article_news.asp?guid=280B17F3-7E87-43A5-9939-C0149C0E0C7F (368 words)

	Tetrabenazine for treatment of Tardive Dyskinesia
		The monoamine depleting drug tetrabenazine has been used for decades in Euro pe and Canada for treatment of tardive dyskinesia and other various movement disorders.
		It is not FDA approved for anything in the USA currently, but is available at various movement disorder clinics in university affiliat ed Neurology departments around the country..via open clinical trials.
		Tetrabenazine works not by "blocking" dopamine receptors, but by actually depleting levels of dopamine and norephinephrine in the brain.
	www.pahealthsystems.com /message127161.html (272 words)

Try your search on: Qwika (all wikis)